Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy

Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997–2003

(2016) Jack Bartram et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy

(2016) Ajay Vora et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels

(2015) Charles G. Mullighan et al.   BLOOD

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232

(2015) M. J. Borowitz et al.   BLOOD

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

(2015) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

(2015) Ching-Hon Pui et al.   LANCET ONCOLOGY

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

(2014) K. Beldjord et al.   BLOOD

Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia

(2014) Maddalena Paganin et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease

(2014) Kathryn G. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

(2014) Josep-Maria Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease–based Treatment is Adequate for Relapse-prone Childhood Acute Lymphoblastic Leukemia with an intrachromosomal amplification of chromosome 21: The experience of the ALL-BFM 2000 trial

(2014) A. Attarbaschi et al.   KLINISCHE PADIATRIE

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

(2014) Ajay Vora et al.   LANCET ONCOLOGY

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

(2012) M. Faham et al.   BLOOD

Minimal residual disease monitoring in childhood acute lymphoblastic leukemia

(2012) Dario Campana   CURRENT OPINION IN HEMATOLOGY

Minimal Residual Disease–Guided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study

(2012) Allen Eng Juh Yeoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia

(2012) Martin Schrappe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

(2011) M. Schrappe et al.   BLOOD

New markers for minimal residual disease detection in acute lymphoblastic leukemia

(2011) E. Coustan-Smith et al.   BLOOD

Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906

(2011) W. Paul Bowman et al.   PEDIATRIC BLOOD & CANCER

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

(2010) P. Stow et al.   BLOOD

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia

(2009) Rosemary Sutton et al.   BRITISH JOURNAL OF HAEMATOLOGY

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

(2009) Giuseppe Basso et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1

(2009) S Jeha et al.   LEUKEMIA

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD